Acadia Healthcare Acquires Quality Addiction Management

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company has purchased the stock of Quality Addiction Management (QAM), an operator of seven comprehensive treatment centers in Wisconsin. The transaction is valued at approximately $53 million and is anticipated to be accretive to 2015 earnings by approximately $0.03 to $0.04 per diluted share.

QAM provides behavioral and addiction treatment services to approximately 2,600 patients per day. QAM’s CEO, Dr. Michael S. Goldstone, will join Acadia as Chief Medical Officer for its comprehensive treatment centers.

Joey Jacobs, Chairman and Chief Executive Officer of Acadia, commented, “We believe this transaction is consistent with our growth strategy of acquiring behavioral health services that serve a community need and complement our existing base of services. QAM has a proven track record and long history of providing quality behavioral treatment services, and we look forward to working with QAM’s caring and qualified staff. We also look forward to working with Dr. Goldstone to expand our clinical services and to further enhance the quality of services delivered throughout Acadia’s comprehensive treatment centers.”

Risk Factors

This news release contains forward-looking statements. Generally words such as “may,” “will,” “should,” “could,” “anticipate,” “expect,” “intend,” “estimate,” “plan,” “continue,” and “believe” or the negative of or other variation on these and other similar expressions identify forward-looking statements. These forward-looking statements are made only as of the date of this news release. We do not undertake to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are based on current expectations and involve risks and uncertainties and our future results could differ significantly from those expressed or implied by our forward-looking statements. Factors that may cause actual results to differ materially include, without limitation, (i) Acadia’s ability to complete acquisitions and successfully integrate the operations of acquired facilities, including the QAM facilities; (ii) Acadia’s ability to add beds, expand services, enhance marketing programs and improve efficiencies at its facilities; (iii) potential reductions in payments received by Acadia from the government and third-party payors; (iv) the occurrence of patient incidents, which could adversely affect the price of our common stock and result in incremental regulatory burdens and governmental investigations; (v) the risk that Acadia may not generate sufficient cash from operations to service its debt and meet its working capital and capital expenditure requirements; and (vi) potential operating difficulties, client preferences, changes in competition and general economic or industry conditions that may prevent Acadia from realizing the expected benefits of its business strategy. These factors and others are more fully described in Acadia’s periodic reports and other filings with the SEC.

About Acadia

Acadia is a provider of inpatient behavioral healthcare services. Acadia operates a network of 201 behavioral healthcare facilities with approximately 8,300 beds in 37 states, the United Kingdom and Puerto Rico. Acadia provides psychiatric and chemical dependency services to its patients in a variety of settings, including inpatient psychiatric hospitals, residential treatment centers, outpatient clinics and therapeutic school-based programs.


Acadia Healthcare Company, Inc.
Brent Turner, 615-861-6000

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.